Main Presentation: “The Role of Heavy Hydrogen (Deuterium) in Translational Medicine” by Laszlo G. Boros, MD
April 27th, 2021 @ 11:00 am PST
Mitochondrial ATP/water biosynthesis steps involve hydrogen transfers via enzymatic cleavage, redox transfer, quantum proton tunneling, delocalization and destabilization; processes that are all compromised by heavy hydrogen isotopes. Therefore, cellular health is best understood by the discrimination of deuterium (2H) during metabolic water production, thereby metabolic water biochemistry and deuterium mediated kinetic isotopic effects become critical for Translational Deutenomics in medicine. The talk will cover research in metabolic profiling and mitochondrial nanomechanics of diseases, the production of deuterium depleted (depleted) metabolic water via nutrition and how deutenomics helps diagnostics via deuterated water metabolic imaging from nutrients.
Join Zoom Meeting by web:
Meeting ID: 879 0205 2033
One tap mobile
+16699006833,,87902052033#,,,,*751760# US (San Jose)
+13462487799,,87902052033#,,,,*751760# US (Houston)
Dial by your location
+1 669 900 6833 US (San Jose)
+1 346 248 7799 US (Houston)
+1 253 215 8782 US (Tacoma)
+1 301 715 8592 US (Washington DC)
+1 312 626 6799 US (Chicago)
+1 929 436 2866 US (New York)
Meeting ID: 879 0205 2033
Find your local number:
About Laszlo G. Boros, MD
Dr. Boros holds a Doctor of Medicine (M.D.) degree from the Albert Szent-Györgyi School of Medicine, Szeged, Hungary. Dr. Boros is currently a Professor of Pediatrics, Endocrinology and Metabolism at the UCLA School of Medicine and investigator at the UCLA Clinical & Translational Science Institute (CTSI), while he is also the Chief Scientific Advisor of SiDMAP, LLC. Dr. Boros studies functional biochemistry for phenotype as well as drug testing that involves library screening, lead optimization and in vitro and in vivo profiling. The core technology involves studying natural steady state and disease/drug induced variations in stable non-radiating isotope variations via cross talk among metabolites and 13C-glucose or deuterium as the labeling substrates.
Dr. Boros is the co-inventor of the targeted 13C tracer fate association platform to study deuterium as an oncoisotope and its depletion by mitochondrial matrix water exchange reactions to prevent oncoisotopic cell transformation by deuterium.
Dr. Boros trained as a house staff in his medical school in gastroenterology after receiving a research training fellowship from the Hungarian Academy of Sciences. Dr. Boros was a visiting Scholar at the Essen School of Medicine in Germany and also worked as a Research Scientist at the Ohio State University, Department of Surgery, in the historic Zollinger-Ellison laboratory. Dr. Boros is the recipient of the C. Williams Hall Outstanding Publication Award from the Academy of Surgical Research of the United States (1997), the Richard E. Weitzman Memorial Research Award from the University of California (2001), the Excellence in Clinical Research Award from the General Clinical Research Center at the Harbor-UCLA Medical Center (2004) and Public Health Impact Investigator Award of the United States Food and Drug Administration (2011). Dr. Boros is an Academic Editor of Nature – Scientific Reports and Medicine, which are peer reviewed periodicals that publish clinical and translational
research papers worldwide.